Physician profile
Waldeck Charles
NPI 1689752123
$2,539.55
in general payments reported to CMS, 2019-2025
21 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $641 · 2021: $539 · 2022: $453 · 2023: $237 · 2024: $213 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $387.00 | 2019-2025 | Rexulti, Abilify Maintena |
| Allergan, INC. | $259.99 | 2019-2020 | |
| Abbvie INC. | $259.00 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $219.08 | 2020-2024 | Trintellix |
| Lundbeck LLC | $201.22 | 2020-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $194.39 | 2020-2025 | Caplyta |
| Alkermes, INC. | $172.75 | 2019-2024 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $155.06 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Vanda Pharmaceuticals INC. | $150.28 | 2020-2024 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $106.58 | 2019-2022 | |
| Neuronetics, INC. | $105.54 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $67.87 | 2021-2023 | Ingrezza |
| Eisai INC. | $61.39 | 2020 | |
| Ironshore Pharmaceuticals INC. | $51.78 | 2020 | |
| Bausch Health US, LLC | $43.79 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $23.09 | 2022 | |
| Corium, LLC | $22.53 | 2023 | Azstarys |
| Shire North American Group INC | $19.05 | 2019 | |
| Axsome Therapeutics, INC. | $14.46 | 2025 | Auvelity |
| Tris Pharma INC | $12.79 | 2022 | |
| Almatica Pharma LLC | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waldeck Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.